{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T02:30:20Z","timestamp":1765333820412,"version":"3.46.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ebr.2025.100839","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:50:16Z","timestamp":1764175816000},"page":"100839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Early antiseizure response to cenobamate (200\u00a0mg\/day) in focal drug-resistant epilepsy: a retrospective single-center analysis"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9493-0263","authenticated-orcid":false,"given":"Ewa","family":"Czapi\u0144ska-Ciepiela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"Kondak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Kowalczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Czapi\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebr.2025.100839_b0005","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2025.100839_b0010","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ebr.2025.100839_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2023.120766","article-title":"Drug-resistant epilepsy: definition, pathophysiology, and management","volume":"452","author":"Mesraoua","year":"2023","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ebr.2025.100839_b0020","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.seizure.2010.10.027","article-title":"Antiepileptic drug therapy the story so far","volume":"19","author":"Brodie","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.ebr.2025.100839_b0025","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.eplepsyres.2011.09.008","article-title":"Antiepileptic drug combinations-have newer agents altered clinical outcomes?","volume":"98","author":"Stephen","year":"2012","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ebr.2025.100839_b0030","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebr.2025.100839_b0035","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.ebr.2025.100839_b0040","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/epi4.12830","article-title":"Cenobamate in refractory epilepsy: overview of treatment options and practical considerations","volume":"8","author":"Schmitz","year":"2023","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.ebr.2025.100839_b0045","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2025.100839_b0050","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2025.100839_b0055","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2025.100839_b0060","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/epi4.12936","article-title":"Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures","volume":"9","author":"Carre\u00f1o","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.ebr.2025.100839_b0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.seizure.2022.02.003","article-title":"Efficacy and safety of adjunctive cenobamate: post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications","volume":"96","author":"Brandt","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.ebr.2025.100839_b0070","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40120-022-00400-5","article-title":"Dose adjustment of concomitant antiseizure medications during cenobamate treatment: expert opinion consensus recommendations","volume":"11","author":"Smith","year":"2022","journal-title":"Neurol Ther"},{"key":"10.1016\/j.ebr.2025.100839_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2023.107242","article-title":"Dose reduction and discontinuation of concomitant antiseizure medications after initiating cenobamate: a retrospective review","volume":"197","author":"Becker","year":"2023","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ebr.2025.100839_b0080","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/epi.17549","article-title":"Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: a \u201creal-world\u201d retrospective study","volume":"64","author":"Pe\u00f1a-Ceballos","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2025.100839_b0085","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1111\/epi.17092","article-title":"Post Hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: effects of dose adjustments of concomitant antiseizure medications","volume":"62","author":"Rosenfeld","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2025.100839_b0090","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s40120-024-00634-5","article-title":"effectiveness and safety of adjunctive cenobamate in people with focal-onset epilepsy: evidence from the first interim analysis of the BLESS study","volume":"13","author":"Lattanzi","year":"2024","journal-title":"Neurol Ther"},{"key":"10.1016\/j.ebr.2025.100839_b0095","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40263-024-01063-6","article-title":"Effect of cenobamate on cognition in patients with drug-resistant epilepsy with focal onset seizures: an exploratory study","volume":"38","author":"Serrano-Castro","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ebr.2025.100839_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1239152","article-title":"Cenobamate as add-on therapy for drug resistant epilepsies: effectiveness, drug to drug interactions and neuropsychological impact. What have we learned from real word evidence?","volume":"14","author":"Pietrafusa","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ebr.2025.100839_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.107014","article-title":"Post Hoc analysis of a phase 3 study for treatment of uncontrolled focal seizures: adjunctive cenobamate dose and seizure reduction by baseline seizure frequency","volume":"186","author":"Aboumatar","year":"2022","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ebr.2025.100839_b0110","first-page":"1099","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter","volume":"61","author":"Sperling","year":"2020","journal-title":"Open-Label Safety Study Epilepsia"},{"key":"10.1016\/j.ebr.2025.100839_b0115","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/epi.17935","article-title":"A global update on cenobamate based on real-world experience in over 100\u2009000 patients","volume":"65","author":"Ferrari","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2025.100839_b0120","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40263-024-01109-9","article-title":"Cenobamate as an early adjunctive treatment in drug-resistant focal-onset seizures: an observational cohort study","volume":"38","author":"Winter","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ebr.2025.100839_b0125","doi-asserted-by":"crossref","DOI":"10.1111\/epi.18357","article-title":"Effectiveness and safety of adjunctive cenobamate in people with focal-onset epilepsy: interim results after 24-week observational period from the BLESS study","author":"Lattanzi","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2025.100839_b0130","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/epi4.12757","article-title":"Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an expanded access program","volume":"8","author":"Villanueva","year":"2023","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.ebr.2025.100839_b0135","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.seizure.2025.05.002","article-title":"Efficacy and safety of cenobamate: a multicenter, retrospective evaluation of real-world clinical practice","volume":"130","author":"Bosak","year":"2025","journal-title":"Seizure"},{"key":"10.1016\/j.ebr.2025.100839_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2023.09.006","article-title":"Real-world experience with cenobamate: a systematic review and meta-analysis","volume":"112","author":"Makridis","year":"2023","journal-title":"Seizure"},{"key":"10.1016\/j.ebr.2025.100839_b0145","article-title":"Effectiveness and safety of adjunctive cenobamate for focal seizures in adults with developmental disability treated in clinical practice","volume":"18","author":"Connor","year":"2022","journal-title":"Epilepsy Behav Rep"},{"key":"10.1016\/j.ebr.2025.100839_b0150","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/epi4.12997","article-title":"Efficacy and safety of add-on antiseizure medications for focal epilepsy: a network meta-analysis","volume":"9","author":"Zhang","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.ebr.2025.100839_b0155","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/epi4.12992","article-title":"The cenobamate KORK study-a prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add-on lacosamide, perampanel, and brivaracetam","volume":"9","author":"Steinhoff","year":"2024","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.ebr.2025.100839_b0160","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal Cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ebr.2025.100839_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106592","article-title":"Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: a post-hoc analysis of a randomized clinical study","volume":"172","author":"Rosenfeld","year":"2021","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ebr.2025.100839_b0170","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/jcm12010129","article-title":"Treatment with cenobamate in adult patients with lennox-gastaut syndrome: a case series","volume":"12","author":"Falcicchio","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ebr.2025.100839_b0175","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/epi.18257","article-title":"Cenobamate as add-on treatment for SCN8A developmental and epileptic encephalopathy","volume":"66","author":"Gjerulfsen","year":"2025","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2025.100839_b0180","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1111\/epi.17427","article-title":"Successful treatment of adult dravet syndrome patients with cenobamate","volume":"63","author":"Makridis","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2025.100839_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2025.03.012","article-title":"Cenobamate in developmental and epileptic encephalopathies and generalized epilepsies: a case report on epilepsy with myoclonic-atonic seizures and systematic review of current evidence","volume":"129","author":"Vlakou","year":"2025","journal-title":"Seizure"}],"container-title":["Epilepsy & Behavior Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986425000991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986425000991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T02:27:36Z","timestamp":1765333656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589986425000991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":37,"alternative-id":["S2589986425000991"],"URL":"https:\/\/doi.org\/10.1016\/j.ebr.2025.100839","relation":{},"ISSN":["2589-9864"],"issn-type":[{"type":"print","value":"2589-9864"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early antiseizure response to cenobamate (200\u00a0mg\/day) in focal drug-resistant epilepsy: a retrospective single-center analysis","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebr.2025.100839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100839"}}